Calendario›REGN›REGN5381 · NATRIX-SBP

REGN5381 · NATRIX-SBP

REGN5381 in Adult Participants With Uncontrolled Hypertension

Ensayo de REGENERON PHARMACEUTICALS, INC. en Uncontrolled Hypertension (del registro, en inglés).

Fase

Fase 2

Estado

Interrumpido

Participantes

34

previstos

Centros

3

Fin del objetivo primario

oct 2025

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en abr 2025.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Sponsor decision».

Qué mide

Unattended Automated Office-Based Blood Pressure (AOBP) Systolic Blood Pressure (SBP) (del registro, en inglés) (en la semana 12)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on uncontrolled hypertension (high blood pressure despite being on one or more antihypertensive drugs). The aim of the study is to see how effective the study drug is in reducing blood pressure. The study is designed as a 2-part study with participants initially enrolling in Part A. Part B of the study will commence and enroll the remaining study participants. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06833190), actualizada en oct 2025.